Mirna Therapeutics Company Profile (NASDAQ:MIRN)

About Mirna Therapeutics (NASDAQ:MIRN)

Mirna Therapeutics logoMirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company's RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MIRN
  • CUSIP: N/A
  • Web: www.mirnarx.com
Capitalization:
  • Market Cap: $30.24 million
  • Outstanding Shares: 20,856,000
Average Prices:
  • 50 Day Moving Avg: $1.89
  • 200 Day Moving Avg: $1.92
  • 52 Week Range: $1.12 - $4.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.30
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.90 per share
  • Price / Book: 0.50
Profitability:
  • EBIDTA: ($21,890,000.00)
  • Return on Equity: -34.47%
  • Return on Assets: -32.77%
Debt:
  • Current Ratio: 21.71%
  • Quick Ratio: 21.71%
Misc:
  • Average Volume: 46,241 shs.
  • Beta: 3.82
  • Short Ratio: 2.74
 

Frequently Asked Questions for Mirna Therapeutics (NASDAQ:MIRN)

What is Mirna Therapeutics' stock symbol?

Mirna Therapeutics trades on the NASDAQ under the ticker symbol "MIRN."

Where is Mirna Therapeutics' stock going? Where will Mirna Therapeutics' stock price be in 2017?

5 analysts have issued 1-year target prices for Mirna Therapeutics' shares. Their predictions range from $1.50 to $13.00. On average, they expect Mirna Therapeutics' share price to reach $4.10 in the next twelve months. View Analyst Ratings for Mirna Therapeutics.

What are analysts saying about Mirna Therapeutics stock?

Here are some recent quotes from research analysts about Mirna Therapeutics stock:

  • 1. According to Zacks Investment Research, "Mirna Therapeutics, Inc. is a biopharmaceutical company which develops microRNA-based oncology therapeutics. The Company's pipeline products include MRX34, miR-Rxlet-7, miR-Rx06, miR-Rx07 and miR-Rx16 which are in preclinical trials. Its lead product, MRX34, is a liposome-encapsulated miR-34 mimic indicated for the treatment of primary liver cancer, solid cancers with liver metastases and hematological malignancies. Mirna Therapeutics, Inc. is headquartered in Austin, Texas. " (1/17/2017)
  • 2. Leerink Swann analysts commented, "We maintain our Market Perform rating for Amgen along with our $193 price target." (9/21/2016)

Who are some of Mirna Therapeutics' key competitors?

Who owns Mirna Therapeutics stock?

Mirna Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sofinnova Management VIII L.L.C. (14.26%), NEA Management Company LLC (14.26%), NEW ENTERPRISE ASSOCIATES 14, L.P. Total Shares: 2,971,517 (14.20%), Vanguard Group Inc. (0.86%) and FMR LLC (0.64%). Company insiders that own Mirna Therapeutics stock include Jon Irvin, Michael Powell and Pfizer Inc. View Institutional Ownership Trends for Mirna Therapeutics.

Who bought Mirna Therapeutics stock? Who is buying Mirna Therapeutics stock?

Mirna Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Mirna Therapeutics stock in the last two years include Michael Powell and Pfizer Inc. View Insider Buying and Selling for Mirna Therapeutics.

How do I buy Mirna Therapeutics stock?

Shares of Mirna Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Mirna Therapeutics stock cost?

One share of Mirna Therapeutics stock can currently be purchased for approximately $1.45.

Analyst Ratings

Consensus Ratings for Mirna Therapeutics (NASDAQ:MIRN) (?)
Ratings Breakdown: 5 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $4.10 (182.78% upside)

Analysts' Ratings History for Mirna Therapeutics (NASDAQ:MIRN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/13/2017Cantor FitzgeraldReiterated RatingHold$2.00LowView Rating Details
11/15/2016HC WainwrightReiterated RatingHoldN/AView Rating Details
9/22/2016Citigroup IncLower Price TargetNeutral$4.50 -> $2.00N/AView Rating Details
9/21/2016Leerink SwannReiterated RatingHold -> Neutral$4.00 -> $1.50N/AView Rating Details
9/21/2016Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Mirna Therapeutics (NASDAQ:MIRN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Mirna Therapeutics (NASDAQ:MIRN)
Current Year EPS Consensus Estimate: $-0.4200 EPS
Next Year EPS Consensus Estimate: $-0.4400 EPS

Dividends

Dividend History for Mirna Therapeutics (NASDAQ:MIRN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mirna Therapeutics (NASDAQ:MIRN)
Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 28.38%
Insider Trades by Quarter for Mirna Therapeutics (NASDAQ:MIRN)
Institutional Ownership by Quarter for Mirna Therapeutics (NASDAQ:MIRN)
Insider Trades by Quarter for Mirna Therapeutics (NASDAQ:MIRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2016Jon IrvinVPSell280$1.43$400.40View SEC Filing  
11/1/2016Jon IrvinVPSell280$1.28$358.40View SEC Filing  
10/11/2016Jon IrvinVPSell150$1.83$274.50View SEC Filing  
10/3/2016Jon IrvinVPSell250$1.93$482.50View SEC Filing  
10/6/2015Michael PowellDirectorBuy857,142$7.00$5,999,994.00View SEC Filing  
10/6/2015Pfizer Incmajor shareholderBuy714,285$7.00$4,999,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Mirna Therapeutics (NASDAQ:MIRN)
Latest Headlines for Mirna Therapeutics (NASDAQ:MIRN)
Source:
DateHeadline
americanbankingnews.com logoMirna Therapeutics Inc (MIRN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - May 19 at 5:08 PM
News IconBRIEF-Synlogic and Mirna therapeutics agree to merger
www.businessinsider.com - May 17 at 9:17 AM
finance.yahoo.com logoBlog Coverage: Mirna Announced Reverse Merger Agreement
finance.yahoo.com - May 17 at 9:17 AM
streetinsider.com logoMirna Therapeutics (MIRN) to Merger with Synlogic
www.streetinsider.com - May 16 at 6:21 PM
finance.yahoo.com logo[$$] Synlogic Strikes Reverse-Merger Deal With Mirna Therapeutics
finance.yahoo.com - May 16 at 6:21 PM
finance.yahoo.com logoAustin cancer-fighting biotech Mirna Therapeutics to cease operations after reverse merger
finance.yahoo.com - May 16 at 6:21 PM
finance.yahoo.com logoSynlogic and Mirna Therapeutics Agree to Merger
finance.yahoo.com - May 16 at 10:31 AM
bizjournals.com logomiRNA Tools and Services Market - Global Opportunity Analysis and Industry Forecast, 2014-2022
www.bizjournals.com - May 10 at 6:38 PM
reuters.com logoBRIEF-Mirna Therapeutics qtrly loss per share $0.24
www.reuters.com - May 10 at 12:27 PM
marketbeat.com logoMirna Therapeutics reports 1Q loss
marketbeat.com - May 10 at 5:20 AM
finance.yahoo.com logoMirna Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 6:14 PM
americanbankingnews.com logoMirna Therapeutics (MIRN) Given News Sentiment Score of 0.12
www.americanbankingnews.com - May 3 at 2:40 PM
americanbankingnews.com logoMirna Therapeutics (MIRN) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 28 at 10:12 PM
americanbankingnews.com logoMirna Therapeutics Inc (MIRN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 24 at 8:23 PM
americanbankingnews.com logoMirna Therapeutics (MIRN) Receiving Somewhat Positive News Coverage, Study Finds
www.americanbankingnews.com - April 22 at 12:17 AM
americanbankingnews.com logoMirna Therapeutics (MIRN) Receiving Positive News Coverage, Study Shows
www.americanbankingnews.com - April 18 at 6:49 PM
americanbankingnews.com logoMirna Therapeutics (MIRN) Receives Daily Coverage Optimism Rating of 0.31
www.americanbankingnews.com - April 14 at 2:50 PM
americanbankingnews.com logoCantor Fitzgerald Reaffirms "Hold" Rating for Mirna Therapeutics Inc (MIRN)
www.americanbankingnews.com - April 13 at 9:20 PM
americanbankingnews.com logoMirna Therapeutics Inc (MIRN) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 7 at 8:01 PM
americanbankingnews.com logoMirna Therapeutics Inc (MIRN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 29 at 1:20 PM
News IconBRIEF-Mirna Therapeutics qtrly net loss attributable to common stockholders $8.7 mln vs $8.9 mln
www.businessinsider.com - March 15 at 6:47 PM
biz.yahoo.com logoMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 15 at 6:47 PM
finance.yahoo.com logoMirna Therapeutics Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016
finance.yahoo.com - March 14 at 10:42 PM
finance.yahoo.com logoZacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, ONE Gas and Avinger
finance.yahoo.com - February 23 at 6:36 PM
finance.yahoo.com logoProfit from These 5 Stocks with Rising P/E Ratio
finance.yahoo.com - February 23 at 6:36 PM
finance.yahoo.com logoZacks.com featured highlights: MannKind, Mirna Therapeutics, NextEra Energy, Sabre and Avinger
finance.yahoo.com - February 23 at 6:36 PM
bizjournals.com logoTexas Innovations in Health Care: More Austin biotech companies go public, but hit stock turbulence
www.bizjournals.com - December 8 at 7:08 PM
finance.yahoo.com logoMIRNA THERAPEUTICS, INC. Financials
finance.yahoo.com - November 24 at 9:26 AM
bizjournals.com logoCentral Texas company halts cancer drug trial after deaths
www.bizjournals.com - November 14 at 6:31 PM
bizjournals.com logoAustin cancer fighters halt drug development after deaths
www.bizjournals.com - November 11 at 5:52 PM
reuters.com logoBRIEF-Mirna therapeutics qtrly net loss was about $5.4 mln
www.reuters.com - November 11 at 8:35 AM
biz.yahoo.com logoMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Other Events
biz.yahoo.com - September 29 at 6:07 PM
streetinsider.com logoMirna Therapeutics (MIRN) Halts Clinical Study of MRX34 Following Severe Adverse Events
www.streetinsider.com - September 22 at 5:53 PM
businesswire.com logoMirna Therapeutics Halts Phase 1 Clinical Study of MRX34
www.businesswire.com - September 22 at 5:53 PM
finance.yahoo.com logoMirna Hits a New Low After Halting Clinical Trial
finance.yahoo.com - September 21 at 5:50 PM
finance.yahoo.com logoMirna Therapeutics (MIRN) Is in Oversold Territory: What's Next?
finance.yahoo.com - September 13 at 10:58 AM
finance.yahoo.com logoValue Screeners Identify Cheap Company Stocks
finance.yahoo.com - August 29 at 6:03 PM
finance.yahoo.com logoMirna Therapeutics downgraded by Leerink Partners
finance.yahoo.com - August 16 at 6:20 PM
reuters.com logoBRIEF-Mirna Therapeutics qtrly net loss attributable to common stockholders $5.64 mln
www.reuters.com - August 15 at 8:24 AM
businesswire.com logomiRagen Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
www.businesswire.com - August 11 at 9:21 AM
biz.yahoo.com logoMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - July 6 at 5:19 PM
finance.yahoo.com logoMirna Therapeutics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference
finance.yahoo.com - July 5 at 7:00 AM
biz.yahoo.com logoMIRNA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a V
biz.yahoo.com - June 30 at 5:30 PM
bizjournals.com logoAustin-area Public Companies list
www.bizjournals.com - June 3 at 8:58 AM

Social

Chart

Mirna Therapeutics (MIRN) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff